Skip to main content

Liver Cancer Clinical Trials

Review the liver cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 163

Tislelizumab Before and After Radiation Therapy for the Treatment of Liver Cancer
Status: Active
Location: 2 locations
Hypofractionated Radiotherapy Followed by Durvalumab with or without Tremelimumab for the Treatment of Liver Cancer
Status: Active
Location: 2 locations
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
Status: Active
Location: 2 locations
Pemigatinib and Durvalumab for the Treatment of FGFR2 Gene Fusion Positive or Rearranged Locally Advanced Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Status: Active
Location: 2 locations
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Status: Active
Location: 2 locations
At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls
Status: Active
Location: 2 locations
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Status: Active
Location: 2 locations
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
Status: Active
Location: 4 locations
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Status: Active
Location: 2 locations
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Status: Active
Location: 3 locations
Ipilimumab and Nivolumab with Stereotactic Body Radiotherapy Followed by Surgical Resection for the Treatment of Locally Advanced Borderline Resectable Hepatocellular Cancer
Status: Active
Location: 2 locations
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor with Liver Metastatic Disease
Status: Active
Location: 2 locations
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Status: Active
Location: 2 locations
Chemoimmunotherapy Combined with Deep Hyperthermia and Spatially-fractionated Radiotherapy for the Treatment of Advanced Biliary Tract Cancer
Status: Active
Location: 2 locations
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Status: Active
Location: 3 locations
Evaluating Response to Atezolizumab and Bevacizumab Treatment in Patients with Gastrointestinal Cancers and Minimal Residual Disease using ctDNA
Status: Active
Location: MedStar Georgetown University Hospital, Washington, District of Columbia
Radiation Treatment (Therasphere) in Combination with Systemic Therapy for the Treatment of Advanced Hepatocellular Carcinoma
Status: Active
Location: Northwestern University, Chicago, Illinois
Gemcitabine, Cisplatin, and Pembrolizumab before and after Surgery for the Treatment of Potentially Resectable Biliary Tract Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Y-90 SIRT in Combination with Durvalumab and Gemcitabine and Cisplatin for the Treatment of Locally Advanced, Unresectable, or Metastatic Biliary Tract Cancer
Status: Active
Location: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Pembrolizumab in Combination with Gemcitabine and Cisplatin for Treating Patients with High-Risk Resectable Intrahepatic Cholangiocarcinoma
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Tremelimumab and Durvalumab for the Treatment of Advanced Liver Cell Cancer in Patients with Child-Pugh-B Cirrhosis
Status: Active
Location: 4 locations
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined with Immune Checkpoint Inhibition after High-Dose External Beam Radiation Therapy in Treating Patients with Unresectable Liver Cancer
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
Status: Active
Location: 2 locations
Enfortumab Vedotin for the Treatment of Patients with Unresectable or Metastatic Colorectal Cancer or Hepatocellular Carcinoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Trifluridine/Tipiracil plus Oxaliplatin for the Treatment of Advanced or Metastatic Biliary Tract Cancer
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio